Supplement: Shire Pharmaceuticals: A Study in Exponential Growth

Shire Pharmaceuticals: A Study in Exponential Growth By Charles Q. Choi RELATED ARTICLES Successful Strategies Margaret Foti: Devoted to cancer research The Launch and the Exit Entrepreneurs Boldly Break New Ground Mark Tykocinski: Open doors lead a scientist to his calling Many Happy Returns: Cephalon celebrates its 20th year Creative Collaboration It's not every company that can go from $7 million in revenues to more than $1.7 billion

| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Successful Strategies

Margaret Foti: Devoted to cancer research

The Launch and the Exit

Entrepreneurs Boldly Break New Ground

Mark Tykocinski: Open doors lead a scientist to his calling

Many Happy Returns: Cephalon celebrates its 20th year

Creative Collaboration

It's not every company that can go from $7 million in revenues to more than $1.7 billion in 10 years, but that's precisely what Shire Pharmaceuticals, whose hub lies in Wayne, Pa., accomplished in the last decade. The key to its success? Seizing opportunities that Big Pharma ignored.

Shire was founded in England in 1986 with just four employees. The company has gone from 540 employees in 1997 to roughly 3,400 now in 12 countries. Shire's rapid growth was driven by a strategy of mergers and acquisitions, with eight in the last 10 years. This strategy is focused on making Shire the leading specialty pharmaceuticals company.

"We consistently focus on relatively ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Charles Q. Choi

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours